-
2
-
-
45749120442
-
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
-
18509184 10.1200/JCO.2007.15.6695 1:CAS:528:DC%2BD1cXnvVOhtr8%3D
-
Yang C-H, Yu C-J, Shih J-Y, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008;26:2745-53.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2745-2753
-
-
Yang, C.-H.1
Yu, C.-J.2
Shih, J.-Y.3
-
3
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D
-
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
-
4
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-39.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
5
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
15329413 10.1073/pnas.0405220101 1:CAS:528:DC%2BD2cXnvFems70%3D
-
Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-11.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
-
6
-
-
78650851231
-
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations
-
Lin C-C, Yang JC-H. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. Drugs 2011;71(1):79-88.
-
(2011)
Drugs
, vol.71
, Issue.1
, pp. 79-88
-
-
Lin, C.-C.1
Yang, J.C.-H.2
-
7
-
-
0037106377
-
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase i trial
-
12228201 10.1200/JCO.2002.03.038 1:CAS:528:DC%2BD38XntVyns7s%3D
-
Herbst RS, Maddox A-M, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815-25.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3815-3825
-
-
Herbst, R.S.1
Maddox, A.-M.2
Rothenberg, M.L.3
-
8
-
-
0036842170
-
Phase i safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
-
12409327 10.1200/JCO.2002.03.100 1:CAS:528:DC%2BD38Xpt1CjtLo%3D
-
Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292-302.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4292-4302
-
-
Baselga, J.1
Rischin, D.2
Ranson, M.3
-
9
-
-
0035398631
-
Phase i and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
-
11432895 1:CAS:528:DC%2BD3MXltlShtbs%3D
-
Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-79.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3267-3279
-
-
Hidalgo, M.1
Siu, L.L.2
Nemunaitis, J.3
-
10
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
-
22285168 10.1016/S1470-2045(11)70393-X 1:CAS:528:DC%2BC38XjsVCgsbk%3D
-
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
11
-
-
84861976809
-
First-SIGNAL: First-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
-
22370314 10.1200/JCO.2011.36.8456 1:CAS:528:DC%2BC38XntVOqtbs%3D
-
Han J-Y, Park K, Kim S-W, et al. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122-8.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1122-1128
-
-
Han, J.-Y.1
Park, K.2
Kim, S.-W.3
-
12
-
-
79960889662
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
-
21783417 10.1016/S1470-2045(11)70184-X 1:CAS:528:DC%2BC3MXpslKhsbY%3D
-
Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-42.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.-L.2
Chen, G.3
-
13
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
-
20022809 10.1016/S1470-2045(09)70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D
-
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-8.
-
(2010)
Lancet Oncol
, vol.11
, pp. 121-128
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
-
14
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
20573926 10.1056/NEJMoa0909530 1:CAS:528:DC%2BC3cXot1Gjt7Y%3D
-
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-8.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
-
15
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK
-
Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.-L.2
Thongprasert, S.3
-
16
-
-
84862819699
-
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
-
22452895 10.1016/S1470-2045(12)70086-4 1:CAS:528:DC%2BC38Xmslyhsbk%3D
-
Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13:539-48.
-
(2012)
Lancet Oncol
, vol.13
, pp. 539-548
-
-
Yang, J.-H.1
Shih, J.-Y.2
Su, W.-C.3
-
17
-
-
84866655838
-
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
-
Yang JC-H, Schuler MH, Yamamoto N, et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. ASCO Meet Abstr 2012;30:LBA7500.
-
(2012)
ASCO Meet Abstr
, vol.30
-
-
Yang, J.C.-H.1
Schuler, M.H.2
Yamamoto, N.3
-
18
-
-
84862785051
-
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
-
22452896 10.1016/S1470-2045(12)70087-6 1:CAS:528:DC%2BC38Xmslyhsbg%3D
-
Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13:528-38.
-
(2012)
Lancet Oncol
, vol.13
, pp. 528-538
-
-
Miller, V.A.1
Hirsh, V.2
Cadranel, J.3
-
19
-
-
33745230152
-
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
-
16670714 1:CAS:528:DC%2BD28XltVOmur8%3D
-
Suzuki R, Hasegawa Y, Baba K, et al. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer. 2006;94:1599-603.
-
(2006)
Br J Cancer
, vol.94
, pp. 1599-1603
-
-
Suzuki, R.1
Hasegawa, Y.2
Baba, K.3
-
20
-
-
33745897107
-
Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer
-
16800967 10.3816/CLC.2006.n.025 1:CAS:528:DC%2BD28XmsFyqtLw%3D
-
Reck M, Buchholz E, Schott-von-Römer K, et al. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. Clin Lung Cancer. 2006;7:406-11.
-
(2006)
Clin Lung Cancer
, vol.7
, pp. 406-411
-
-
Reck, M.1
Buchholz, E.2
Schott-Von-Römer, K.3
-
21
-
-
33644845421
-
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
-
16382114 10.1200/JCO.2005.02.5825 1:CAS:528:DC%2BD28Xot1CgsA%3D%3D
-
Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 2006;24:64-9.
-
(2006)
J Clin Oncol
, vol.24
, pp. 64-69
-
-
Niho, S.1
Kubota, K.2
Goto, K.3
-
22
-
-
33750080906
-
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer
-
17409866
-
Kimura H, Kasahara K, Shibata K, et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol. 2006;1:260-7.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 260-267
-
-
Kimura, H.1
Kasahara, K.2
Shibata, K.3
-
23
-
-
41549125361
-
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
-
18096565 10.1093/annonc/mdm564
-
D'Addario G, Rauch D, Stupp R, et al. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol. 2008;19:739-45.
-
(2008)
Ann Oncol
, vol.19
, pp. 739-745
-
-
D'Addario, G.1
Rauch, D.2
Stupp, R.3
-
24
-
-
33750700477
-
Erlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II study
-
17062680 10.1158/1078-0432.CCR-06-0260 1:CAS:528:DC%2BD28XhtFWhsbjF
-
Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 2006;12:6049-55.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6049-6055
-
-
Giaccone, G.1
Gallegos Ruiz, M.2
Le Chevalier, T.3
-
25
-
-
80054757868
-
Erlotinib in first-line therapy for non-small cell lung cancer: A prospective phase II study
-
21965761 1:CAS:528:DC%2BC3MXhtl2rsL%2FJ
-
Choi DR, Lee DH, Choi C-M, et al. Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study. Anticancer Res. 2011;31:3457-62.
-
(2011)
Anticancer Res
, vol.31
, pp. 3457-3462
-
-
Choi, D.R.1
Lee, D.H.2
Choi, C.-M.3
-
26
-
-
34248385777
-
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
-
17409969 10.1097/01243894-200610000-00014
-
Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1:847-55.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 847-855
-
-
Chang, A.1
Parikh, P.2
Thongprasert, S.3
-
27
-
-
33645302908
-
A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer
-
16574039 10.1185/030079906X89847 1:CAS:528:DC%2BD28XjvV2htLo%3D
-
Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006;22:561-73.
-
(2006)
Curr Med Res Opin
, vol.22
, pp. 561-573
-
-
Park, K.1
Goto, K.2
-
28
-
-
10844231985
-
Mutations of the epidermal growth factor receptor gene in lung cancer
-
15604253 10.1158/0008-5472.CAN-04-2818 1:CAS:528:DC%2BD2cXhtVOmsL3P
-
Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer. Cancer Res. 2004;64:8919-23.
-
(2004)
Cancer Res
, vol.64
, pp. 8919-8923
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
-
29
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
15741570 10.1093/jnci/dji055 1:CAS:528:DC%2BD2MXitV2jsb4%3D
-
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-46.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
-
30
-
-
33746789922
-
Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
-
16785471 10.1200/JCO.2005.05.4692 1:CAS:528:DC%2BD28Xot1Kis7g%3D
-
Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340-6.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3340-3346
-
-
Inoue, A.1
Suzuki, T.2
Fukuhara, T.3
-
31
-
-
33750205340
-
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
-
17047648 10.1038/sj.bjc.6603393 1:CAS:528:DC%2BD28XhtVyitbfO
-
Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006;95:998-1004.
-
(2006)
Br J Cancer
, vol.95
, pp. 998-1004
-
-
Asahina, H.1
Yamazaki, K.2
Kinoshita, I.3
-
32
-
-
45149084723
-
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
-
18458038 10.1200/JCO.2007.14.8494 1:CAS:528:DC%2BD1cXnsVKhtbk%3D
-
Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2442-2449
-
-
Sequist, L.V.1
Martins, R.G.2
Spigel, D.3
-
33
-
-
33947504732
-
Phase II clinical trial of chemotherapy-naïve patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer
-
17228019 10.1200/JCO.2006.07.5754 1:CAS:528:DC%2BD2sXjvVKmt7o%3D
-
Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naïve patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760-6.
-
(2007)
J Clin Oncol
, vol.25
, pp. 760-766
-
-
Jackman, D.M.1
Yeap, B.Y.2
Lindeman, N.I.3
-
34
-
-
52049096854
-
Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study
-
18779612 10.1200/JCO.2007.15.0672
-
Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008;26:4253-60.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4253-4260
-
-
Crinò, L.1
Cappuzzo, F.2
Zatloukal, P.3
-
35
-
-
84858339030
-
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older
-
Chen Y-M, Tsai C-M, Fan W-C et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol 2012;7:412-418.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 412-418
-
-
Chen, Y.-M.1
Tsai, C.-M.2
Fan, W.-C.3
-
36
-
-
63049132774
-
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
-
19224850 10.1200/JCO.2008.18.7658 1:CAS:528:DC%2BD1MXksF2iu7c%3D
-
Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394-400.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1394-1400
-
-
Inoue, A.1
Kobayashi, K.2
Usui, K.3
-
37
-
-
84865686581
-
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study
-
Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7:1417-1422.
-
(2012)
J Thorac Oncol.
, vol.7
, pp. 1417-1422
-
-
Maemondo, M.1
Minegishi, Y.2
Inoue, A.3
-
38
-
-
84865154870
-
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial
-
Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol. 2012;30:3002-11.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 3002-3011
-
-
Gridelli, C.1
Ciardiello, F.2
Gallo, C.3
-
39
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
-
18506025 10.1200/JCO.2007.15.0375 1:CAS:528:DC%2BD1cXpvVWmtLg%3D
-
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
-
40
-
-
79960702788
-
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
-
Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866-74.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 2866-2874
-
-
Fukuoka, M.1
Wu, Y.-L.2
Thongprasert, S.3
-
41
-
-
23844465454
-
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
-
16105816 10.1158/0008-5472.CAN-05-0331 1:CAS:528:DC%2BD2MXns1Wrurk%3D
-
Nagai Y, Miyazawa H, Huqun TT, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65:7276-82.
-
(2005)
Cancer Res
, vol.65
, pp. 7276-7282
-
-
Nagai, Y.1
Miyazawa, H.2
Huqun, T.T.3
-
42
-
-
83455167490
-
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations
-
Inoue A, Kobayashi K, Maemondo M, et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. ASCO Meet Abstr. 2011;29:7519.
-
(2011)
ASCO Meet Abstr
, vol.29
, pp. 7519
-
-
Inoue, A.1
Kobayashi, K.2
Maemondo, M.3
-
43
-
-
33745985181
-
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer
-
10.2353/jmoldx.2006.050104 1:CAS:528:DC%2BD28XnsFGnsLc%3D
-
Yatabe Y, Hida T, Horio Y, et al. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn JMD. 2006;8:335-41.
-
(2006)
J Mol Diagn JMD
, vol.8
, pp. 335-341
-
-
Yatabe, Y.1
Hida, T.2
Horio, Y.3
-
44
-
-
0033566652
-
Statistical principles for clinical trials (ICH E9): An introductory note on an international guideline
-
10440877 10.1002/(SICI)1097-0258(19990815)18:15<1903: AID-SIM188>3.0.CO;2-F 1:STN:280:DyaK1MzntVamtw%3D%3D
-
Lewis JA. Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. Stat Med. 1999;18:1903-42.
-
(1999)
Stat Med
, vol.18
, pp. 1903-1942
-
-
Lewis, J.A.1
-
45
-
-
84875912476
-
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)
-
Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). ASCO Meet Abstr. 2012;30:7521.
-
(2012)
ASCO Meet Abstr
, vol.30
, pp. 7521
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
-
46
-
-
84866756012
-
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
-
Zhou C, Wu YL, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2012;30:7520.
-
(2012)
ASCO Meet Abstr
, vol.30
, pp. 7520
-
-
Zhou, C.1
Wu, Y.L.2
Liu, X.3
-
47
-
-
84875946275
-
EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study
-
Rosell R, Molina-Vila MA, Taron M, et al. EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study. ASCO Meet Abstr. 2012;30:7522.
-
(2012)
ASCO Meet Abstr
, vol.30
, pp. 7522
-
-
Rosell, R.1
Molina-Vila, M.A.2
Taron, M.3
-
48
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
11784875 10.1056/NEJMoa011954 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D
-
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8.
-
(2002)
N Engl J Med
, vol.346
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
-
49
-
-
77951876335
-
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: Results of an exploratory subgroup analysis of a phase III trial
-
Yang C-H, Simms L, Park K et al. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol. 2010;5:688-695.
-
(2010)
J Thorac Oncol.
, vol.5
, pp. 688-695
-
-
Yang, C.-H.1
Simms, L.2
Park, K.3
-
50
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL
-
19188680 10.1200/JCO.2007.14.5466 1:CAS:528:DC%2BD1MXktFKhsL0%3D
-
Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227-34.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1227-1234
-
-
Reck, M.1
Von Pawel, J.2
Zatloukal, P.3
-
51
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI
-
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
52
-
-
77953541527
-
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
-
20493771 10.1016/S1470-2045(10)70112-1 1:CAS:528:DC%2BC3cXntVCksb0%3D
-
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521-9.
-
(2010)
Lancet Oncol
, vol.11
, pp. 521-529
-
-
Cappuzzo, F.1
Ciuleanu, T.2
Stelmakh, L.3
-
53
-
-
70350225538
-
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
-
19767093 10.1016/S0140-6736(09)61497-5 1:CAS:528:DC%2BD1MXhtlSru7jL
-
Ciuleanu T. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-40.
-
(2009)
Lancet
, vol.374
, pp. 1432-1440
-
-
Ciuleanu, T.1
-
54
-
-
84857507055
-
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial
-
22341744 10.1016/S1470-2045(12)70063-3 1:CAS:528:DC%2BC38XjsVCgsbY%3D
-
Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247-55.
-
(2012)
Lancet Oncol
, vol.13
, pp. 247-255
-
-
Paz-Ares, L.1
De Marinis, F.2
Dediu, M.3
-
55
-
-
73349111952
-
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials
-
19826121 10.1200/JCO.2009.22.4329
-
Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009;27:5958-64.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5958-5964
-
-
Bhattacharya, S.1
Fyfe, G.2
Gray, R.J.3
Sargent, D.J.4
-
56
-
-
78649478110
-
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
-
20497965 10.1093/annonc/mdq204 1:STN:280:DC%2BC3cbotFGqtQ%3D%3D
-
Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 2010;21:2324-32.
-
(2010)
Ann Oncol
, vol.21
, pp. 2324-2332
-
-
Soria, J.C.1
Massard, C.2
Le Chevalier, T.3
-
57
-
-
79957520182
-
Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials
-
21464420 10.1200/JCO.2010.32.3683 1:CAS:528:DC%2BC3MXosF2ku74%3D
-
Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol. 2011;29:2104-20.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2104-2120
-
-
Claassens, L.1
Van Meerbeeck, J.2
Coens, C.3
-
58
-
-
0036184207
-
What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592
-
11864800 10.1016/S0895-4356(01)00477-2
-
Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55:285-95.
-
(2002)
J Clin Epidemiol
, vol.55
, pp. 285-295
-
-
Cella, D.1
Eton, D.T.2
Fairclough, D.L.3
-
59
-
-
80054882063
-
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
-
Thongprasert S, Duffield E, Saijo, N et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011;6:1872-1880.
-
(2011)
J Thorac Oncol.
, vol.6
, pp. 1872-1880
-
-
Thongprasert, S.1
Duffield, E.2
Saijo, N.3
-
60
-
-
84859422412
-
Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC)
-
Zhou C, Wu YL, Chen G, et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2011;29:7520.
-
(2011)
ASCO Meet Abstr
, vol.29
, pp. 7520
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
-
61
-
-
79957823572
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial
-
21621716 10.1016/S0140-6736(11)60545-X 1:CAS:528:DC%2BC3MXmslKnu7Y%3D
-
Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377:1846-54.
-
(2011)
Lancet
, vol.377
, pp. 1846-1854
-
-
Herbst, R.S.1
Ansari, R.2
Bustin, F.3
-
62
-
-
78449274913
-
Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
-
Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2010;28:7526.
-
(2010)
ASCO Meet Abstr
, vol.28
, pp. 7526
-
-
Kabbinavar, F.F.1
Miller, V.A.2
Johnson, B.E.3
-
63
-
-
33847401939
-
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
-
17308046 10.1158/1535-7163.MCT-06-0416 1:CAS:528:DC%2BD2sXhvVWku7s%3D
-
Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007;6:471-83.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 471-483
-
-
Wu, W.1
Onn, A.2
Isobe, T.3
-
64
-
-
80053531654
-
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design
-
21856766 10.1158/1078-0432.CCR-11-1468 1:CAS:528:DC%2BC3MXht1Ggs7nF
-
Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011;17:6298-303.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6298-6303
-
-
Chaft, J.E.1
Oxnard, G.R.2
Sima, C.S.3
-
65
-
-
84867062177
-
ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
-
Park K, Tsai C-M, Ahn M-j, et al. ASPIRATION: phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). ASCO Meet Abstr 2012;30:TPS7614.
-
(2012)
ASCO Meet Abstr
, vol.30
-
-
Park, K.1
Tsai, C.-M.2
Ahn, M.-J.3
-
66
-
-
49149118719
-
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
-
18408761 10.1038/onc.2008.109 1:CAS:528:DC%2BD1cXptlKnsbk%3D
-
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702-11.
-
(2008)
Oncogene
, vol.27
, pp. 4702-4711
-
-
Li, D.1
Ambrogio, L.2
Shimamura, T.3
-
67
-
-
77957585027
-
Phase i trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
-
20679611 10.1200/JCO.2009.26.7278 1:CAS:528:DC%2BC3cXht1eqsbzF
-
Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28:3965-72.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3965-3972
-
-
Yap, T.A.1
Vidal, L.2
Adam, J.3
-
68
-
-
84866255620
-
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
-
22753918 10.1200/JCO.2011.40.9433 1:CAS:528:DC%2BC38Xhs1Glt7%2FK
-
Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3337-44.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3337-3344
-
-
Ramalingam, S.S.1
Blackhall, F.2
Krzakowski, M.3
-
69
-
-
84873084476
-
ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC) - A randomized double-blind phase III study
-
Boyer MJ, Janne PA, Mok T, et al. ARCHER: dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC) - a randomized double-blind phase III study. ASCO Meet Abstr 2012;30:TPS7615.
-
(2012)
ASCO Meet Abstr
, vol.30
-
-
Boyer, M.J.1
Janne, P.A.2
Mok, T.3
-
70
-
-
84878860692
-
Dacomitinib (PF-00299804), an irreversible pan-Her tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or Her2-mutant or -amplified lung cancers
-
Kris M, Goldberg Z, Janne PA, et al. Dacomitinib (PF-00299804), an irreversible pan-Her tyrosine kinase inhibitor (TKI), for first-line treatment of EGFR-mutant or Her2-mutant or -amplified lung cancers. Ann Oncol. 2012;23:ix400-46.
-
(2012)
Ann Oncol.
, vol.23
-
-
Kris, M.1
Goldberg, Z.2
Janne, P.A.3
-
71
-
-
80052194689
-
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: A meta-analysis
-
21325444 10.1093/annonc/mdq742 1:STN:280:DC%2BC3MflvFerug%3D%3D
-
Bria E, Milella M, Cuppone F, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol. 2011;22:2277-85.
-
(2011)
Ann Oncol
, vol.22
, pp. 2277-2285
-
-
Bria, E.1
Milella, M.2
Cuppone, F.3
-
72
-
-
79957492069
-
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
-
21482992 10.1200/JCO.2010.31.8923
-
Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology Provisional Clinical Opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121-7.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2121-2127
-
-
Keedy, V.L.1
Temin, S.2
Somerfield, M.R.3
|